Obesity in people living with type 1 diabetes.

Autor:	Van der Schueren B; Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium; Laboratory of Clinical and Experimental Endocrinology, University of Leuven, Leuven, Belgium. Electronic address: bart.vanderschueren@uzleuven.be., Ellis D; Laboratory of Clinical and Experimental Endocrinology, University of Leuven, Leuven, Belgium., Faradji RN; Endocrinology and Diabetes, Clinica EnDi, Mexico City, Mexico; Centro Medico ABC, Mexico City, Mexico., Al-Ozairi E; Department of Clinical Research and Clinical Trials, Dasman Diabetes Institute, Dasman, Kuwait., Rosen J; JDRF International, New York, NY, USA., Mathieu C; Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium; Laboratory of Clinical and Experimental Endocrinology, University of Leuven, Leuven, Belgium.
Jazyk:	angličtina
Zdroj:	The lancet. Diabetes & endocrinology [Lancet Diabetes Endocrinol] 2021 Nov; Vol. 9 (11), pp. 776-785. Date of Electronic Publication: 2021 Sep 30.
DOI:	10.1016/S2213-8587(21)00246-1
Abstrakt:	Although type 1 diabetes is traditionally considered a disease of lean people, overweight and obesity are becoming increasingly more common in individuals with type 1 diabetes. Non-physiological insulin replacement that causes peripheral hyperinsulinaemia, insulin profiles that do not match basal and mealtime insulin needs, defensive snacking to avoid hypoglycaemia, or a combination of these, are believed to affect body composition and drive excessive accumulation of body fat in people with type 1 diabetes. The consequences of overweight or obesity in people with type 1 diabetes are of particular concern, as they increase the risk of both diabetes-related and obesity-related complications, including cardiovascular disease, stroke, and various types of cancer. In this Review, we summarise the current understanding of the aetiology and consequences of excessive bodyweight in people with type 1 diabetes and highlight the need to optimise future prevention and treatment strategies in this population. Competing Interests: Declaration of interests CM reports consulting fees from Novo Nordisk, Sanofi, Merck Sharp & Dohme, Eli Lilly, AstraZeneca, Boehringer Ingelheim, Roche, Medtronic, ActoBio Therapeutics, Pfizer, Insulet, and Zealand Pharma; and serves or has served on the speaker bureau for Novo Nordisk, Sanofi, Eli Lilly, Boehringer Ingelheim, AstraZeneca, and Novartis. RNF reports personal fees from Novo Nordisk, Sanofi, Abbott, and Medtronic; participation on an advisory board for Novo Nordisk, Sanofi, and Abbott; holds a fiduciary role in international relations for Sociedad Mexicana de Nutricion y Endocrinologa (SMNE); and has received product from Novo Nordisk, Sanofi, Abbott, Medtronic, Eli Lilly, AstraZeneca, Merck Sharp & Dohme, and Pfizer. All other authors declare no competing interests. (Copyright © 2021 Elsevier Ltd. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu